Should I buy BioLife Solutions, Inc. (BLFS) stock or is it too late?

BioLife Solutions, Inc. · Health Care · price $39

See the full BioLife Solutions, Inc. (BLFS) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Jefferies — 61% of its targets hit on this sector (137 calls tested). It aims for $31 (-20 %), call made on July 24, 2026, maturing on July 24, 2027 (82 d ago).

The 3 reliable analysts $31-20 %

The 2 other firms $31-20 %

How to read it: the 3 reliable firms are not filtered by optimism — 0 aim above the price, 3 below, hence their $31 median. “The 2 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on BioLife Solutions, Inc.

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
HC Wainwright & Co.	0 %	0.0 %	8	$31 -20%
Keybanc	0 %	0.0 %	5	$33 -15%

In short — Should you invest in BioLife Solutions, Inc.? Is it too late, still worth it? Analysts are split (0% buy, median target $31, i.e. -20%). But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Few solid positives from analysts right now: of 6 ratings, only 0 buys, and the median price target ($31) is -20% below the price ($39). Caution prevails.

⚠️ Reasons to hesitate

Even the most reliable firm on BLFS, HC Wainwright & Co. (0% hit rate, 8 scored calls), only targets $31 (call made on July 22, 2026, maturing on July 22, 2027) (-20%) in its most recent call, and $32 (call made on November 24, 2025, maturing on November 24, 2026) (-17%) in the one coming due soonest. The stock may already have run past its target.
The consensus is not unanimous: of 6 ratings, 6 are neutral.
Limited upside: the median target is only -20% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on BLFS

Median target $31 (-20%) · 6 ratings · Hold consensus

Strong Buy00%

Buy00%

Hold6100%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in BioLife Solutions, Inc. now?

We won't decide for you. The facts: 0% of analysts rate it a buy, median target $31 (-20%), and HC Wainwright & Co. (most reliable on BLFS, 0%) targets $31. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in BioLife Solutions, Inc.?

The stated upside is small: the median target ($31) sits just -20% from the price ($39) (most reliable on BLFS: HC Wainwright & Co., 0%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is BioLife Solutions, Inc. still worth investing in?

It depends on the gap between the price ($39) and its estimated value: analysts target $31 on median (-20%), with 0% buys (most reliable on BLFS: HC Wainwright & Co., 0%). Cross-check with their real reliability on BLFS and the cautions above. Information, not advice.

What's the main risk in buying BLFS?

Even the most reliable firm on BLFS, HC Wainwright & Co. (0% hit rate, 8 scored calls), only targets $31 (call made on July 22, 2026, maturing on July 22, 2027) (-20%) in its most recent call, and $32 (call made on November 24, 2025, maturing on November 24, 2026) (-17%) in the one coming due soonest. The stock may already have run past its target.

→ Go deeper: the full BioLife Solutions, Inc. profile (consensus, analyst reliability, price target, performance).